Cardiometabolic risks of blonanserin and perospirone in the management of schizophrenia: a systematic review and meta-analysis of randomized controlled trials.
Cardiometabolic risks of blonanserin and perospirone in the management of schizophrenia: a systematic review and meta-analysis of randomized controlled trials.
复制标题
DOI：
10.1371/journal.pone.0088049
复制
发表时间：
2014
期刊：
影响因子：
3.7
通讯作者：
Iwata N
中科院分区：
文献类型：
--
作者：
Kishi T;Matsuda Y;Iwata N
本研究旨在评估在精神分裂症患者的治疗中使用布洛宁色林和培螺酮与其他抗精神病药相比的心脏代谢风险[体重增加、血脂水平(总胆固醇和甘油三酯)、血糖水平、糖化血红蛋白(HbA1c)水平和校正QT间期延长]。我们对来自随机对照试验的患者数据进行了系统的回顾和荟萃分析，这些试验比较了布洛宁色林或培螺酮与其他抗精神病药物。总共确定了4篇布洛宁研究(n = 1080)[与利培酮(2篇研究，n = 508)；与氟哌啶醇(2篇研究，n = 572)]。与利培酮相比，布洛南色林的体重增加较少(加权平均差异 = −为0.86，95%可信区间 = −为1.36至−为0.36，p = 为0.0008；2项研究，480名患者)。然而，在血脂、血糖、糖化血红蛋白水平或QTC延长方面，布隆色林与利培酮或氟哌啶醇之间没有显著差异。在培螺酮研究中，确定了5项研究[562例成年精神分裂症患者随机分为培螺酮(n = )256例、奥氮平(n = 20例)、奎硫平(n = 28例)、利培酮(n = 53例)、阿立哌唑(n = 49例)、氟哌啶醇(n = 75例)或莫沙帕明(n = 81例)]。培螺酮在体重增加和总胆固醇水平方面与其他抗精神病药物没有不同。我们的结果表明，与其他抗精神病药物相比，Blonanserin与体重增加的比例较低。因为研究的数量很少，所以建议进行更多的患者数量更多的临床对照试验。
The present study aimed to evaluate cardiometabolic risks [weight gain, blood lipid levels (total cholesterol and triglycerides), blood glucose levels, hemoglobin A1c (HbA1c) levels, and corrected QT interval (QTc) prolongation] associated with the use of blonanserin and perospirone versus other antipsychotics in the management of patients with schizophrenia. We conducted a systematic review and meta-analysis of patient data from randomized controlled trials comparing blonanserin or perospirone with other antipsychotics. In total, 4 blonanserin studies (n = 1080) were identified [vs. risperidone (2 studies, n = 508); vs. haloperidol (2 studies, n = 572)]. Blonanserin produced less weight gain compared with risperidone (weighted mean difference = −0.86, 95% confidence intervals = −1.36 to −0.36, p = 0.0008; 2 studies, 480 patients). However, no significant differences were observed in blood lipid, glucose, and HbA1c levels or QTc prolongation between blonanserin and risperidone or haloperidol. For perospirone studies, 5 studies [562 adult patients with schizophrenia randomized to perospirone (n = 256), olanzapine (n = 20), quetiapine (n = 28), risperidone (n = 53), aripiprazole (n = 49), haloperidol (n = 75), or mosapramine (n = 81)] were identified. Perospirone did not differ from other antipsychotics with regard to weight gain and total cholesterol levels. Our results suggest that blonanserin is associated with a lower of weight gain compared with other antipsychotics. Because the number of studies was small, additional controlled clinical trials with larger number of patients are indicated.
登录
查看更多内容
影响因子：
15.8
作者：
Moher D;Liberati A;Tetzlaff J;Altman DG;PRISMA Group
通讯作者：
PRISMA Group
影响因子：
168.9
作者：
Leucht, Stefan;Corves, Caroline;Davis, John M.
通讯作者：
Davis, John M.
DOI：
10.1016/0197-2456(86)90046-2
发表时间：
1986-09-01
期刊：
CONTROLLED CLINICAL TRIALS
影响因子：
--
作者：
DERSIMONIAN, R;LAIRD, N
通讯作者：
LAIRD, N
影响因子：
120.7
作者：
Correll, Christoph U.;Manu, Peter;Olshanskiy, Vladimir;Napolitano, Barbara;Kane, John M.;Malhotra, Anil K.
通讯作者：
Malhotra, Anil K.
影响因子：
6
作者：
Garcia, Esther;Robert, Marta;Terazawa, Yoshikatsu
通讯作者：
Terazawa, Yoshikatsu